Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market Report 2026

Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market Overview

• Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy market size has reached to $1.22 billion in 2025 • Expected to grow to $1.79 billion in 2030 at a compound annual growth rate (CAGR) of 8% • Growth Driver: Rising Adoption Of Personalized Medicine Driving Growth In The Market Due To Advances In Genomics And Targeted Therapeutics • Market Trend: Advancing Personalized Immunotherapy Through Allele-Specific Patient Selection • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market?

Human leukocyte antigen (HLA) typing for oncology immunotherapy is a genetic testing process that identifies a patient’s HLA profile, which governs immune system recognition of cells. It is used to guide personalized cancer immunotherapies, such as adoptive T-cell therapies or cancer vaccines, by matching treatments to the patient’s immune compatibility. It helps predict therapy effectiveness, minimize immune-related adverse reactions, and optimize treatment outcomes in precision oncology. The main technologies of human leukocyte antigen (HLA) typing for oncology immunotherapy include polymerase chain reaction (PCR)-based, sequencing-based, sequence-specific oligonucleotide (SSO), sequence-specific primer (SSP), and others. Polymerase chain reaction (PCR)-based refers to techniques or tests that use PCR to amplify specific DNA sequences for detection, analysis, or research purposes. The various product types include reagents and kits, instruments, and software. The key applications of cancer diagnosis, personalized medicine, research, clinical trials, and other applications, while the end-use includes hospitals and diagnostic laboratories, research institutes, academic centers, pharmaceutical and biotechnology companies, and other end-users.

What Is The Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market Growth Forecast?

The human leukocyte antigen (HLA) typing for oncology immunotherapy market size is expected to see strong growth in the next few years. It will grow to $1.79 billion in 2030 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to growing pipeline of cell and gene therapies, increasing investment in personalized immunotherapy research, rising demand for companion diagnostics, expansion of oncology clinical trials worldwide, increasing regulatory support for precision medicine. Major trends in the forecast period include increasing adoption of next generation sequencing based hla typing, rising integration of hla profiling in adoptive t cell therapies, growing use of high resolution hla typing in clinical trials, expansion of personalized cancer vaccine development, rising focus on predictive immune compatibility testing.

Global Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market Segmentation

1) By Technology: Polymerase Chain Reaction (PCR)-Based, Sequencing-Based, Sequence-Specific Oligonucleotide (SSO), Sequence-Specific Primer (SSP), Other Technologies 2) By Product Type: Reagents And Kits, Instruments, Software 3) By Application: Cancer Diagnosis, Personalized Medicine, Research, Clinical Trials, Other Applications 4) By End-User: Hospitals And Diagnostic Laboratories, Research Institutes, Academic Centers, Pharmaceutical And Biotechnology Companies, Other End-Users Subsegments: 1) By Polymerase Chain Reaction Based: Real Time Polymerase Chain Reaction, Nested Polymerase Chain Reaction, Multiplex Polymerase Chain Reaction, Digital Polymerase Chain Reaction 2) By Sequencing Based: Next Generation Sequencing, Sanger Sequencing, Whole Genome Sequencing, Targeted Gene Sequencing 3) By Sequence Specific Oligonucleotide: Luminex Based Sequence Specific Oligonucleotide, Microarray Based Sequence Specific Oligonucleotide, Bead Based Sequence Specific Oligonucleotide, Plate Based Sequence Specific Oligonucleotide 4) By Sequence Specific Primer: Conventional Sequence Specific Primer, Multiplex Sequence Specific Primer, Real Time Sequence Specific Primer, Nested Sequence Specific Primer 5) By Other Technologies: Flow Cytometry Based Typing, Mass Spectrometry Based Typing, Immunoassay Based Typing, Hybridization Based Typing

What Is The Driver Of The Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market?

The growing adoption of personalized medicine is expected to propel the growth of the human leukocyte antigen (HLA) typing for oncology immunotherapy market going forward. Personalized medicine refers to tailoring medical treatment and healthcare decisions to an individual’s genetic, molecular, and clinical profile for more precise and effective therapy. Personalized medicine is increasing due to advances in genomics, which allow clinicians to identify genetic variations that influence disease risk and drug response, enabling more targeted and effective treatments. Human leukocyte antigen typing enables personalized oncology immunotherapy by identifying a patient’s unique immune profile to tailor treatments that optimize tumor antigen recognition and immune response. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based nonprofit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from 6 in 2022, including the newly approved personalized treatments for 2023, which also include 7 cancer drugs and 3 for other diseases and conditions. Therefore, the growing adoption of personalized medicine is driving the growth of the human leukocyte antigen (HLA) typing for oncology immunotherapy industry.

Key Players In The Global Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market

Major companies operating in the human leukocyte antigen (HLA) typing for oncology immunotherapy market are Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson Company, Eurofins Scientific SE, Illumina Inc., Werfen, QIAGEN N.V., Versiti Inc., CareDx Inc., Oxford Nanopore Technologies Plc., Pacific Biosciences of California Inc., Takara Bio Inc., HistoGenetics LLC, Biofortuna Limited, Bio‑Rad Laboratories Inc., DKMS Life Science Lab, ClinImmune Inc., BGI Genomics Co. Ltd., Immudex A/S, ProImmune Ltd.

Global Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market Trends and Insights

Major companies operating in the human leukocyte antigen (HLA) typing for oncology immunotherapy market are focusing on developing innovative solutions such as allele-specific patient selection to enhance personalized immunotherapy efficacy and improve clinical outcomes. Allele-specific patient selection refers to identifying patients based on their specific HLA gene variants to tailor immunotherapy for optimal effectiveness. For instance, in August 2024, Thermo Fisher Scientific Inc., a US-based biotechnology company, received approval from the FDA for the SeCore HLA typing kit for use as a companion diagnostic with a T-cell receptor therapy for synovial sarcoma. This approval expands HLA sequencing from transplant diagnostics into oncology immunotherapy by enabling precise patient selection for TCR-based treatments targeting tumor antigens.

What Are Latest Mergers And Acquisitions In The Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market?

In November 2023, Genome Diagnostics B.V., a Netherlands-based molecular diagnostics company, partnered with OSE Immunotherapeutics SA to develop an HLA A*02 companion diagnostic for cancer patients. With this partnership companies aim to develop and validate an NGS-based companion diagnostic test for HLA-A*02 typing to identify eligible NSCLC patients for OSE's Tedopi cancer vaccine in its Phase 3 trial. OSE Immunotherapeutics SA is a France-based clinical-stage biotechnology company focused on developing first-in-class, next-generation immuno-oncology and immuno-inflammation therapies.

Regional Insights

North America was the largest region in the human leukocyte antigen (HLA) typing for oncology immunotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market?

The human leukocyte antigen (HLA) typing for oncology immunotherapy market consists of revenues earned by entities by providing services such as tissue and organ matching, immunotherapy response prediction, and personalized therapy planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The human leukocyte antigen (HLA) typing for oncology immunotherapy market also includes sales of multiplex detection systems, real-time polymerase chain reaction (PCR) thermal cyclers, and standard PCR thermal cyclers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data And Analysis Are Included In The Human Leukocyte Antigen (HLA) Typing For Oncology Immunotherapy Market Report 2026?

The human leukocyte antigen (hla) typing for oncology immunotherapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the human leukocyte antigen (hla) typing for oncology immunotherapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.